Overview
Parkinsonian symptoms can arise from occupational exposure to carbon disulfide (CS2), primarily through the formation and detection of 2-thiothiazolidine-4-carboxylic acid (TTCA) in urine, indicating neurotoxic effects on dopaminergic pathways.Diagnosis
Key Diagnostic Biomarker: Detection of 2-thiothiazolidine-4-carboxylic acid (TTCA) in urine using HPLC 1.
Exposure Assessment: Evaluate occupational exposure to CS2 levels, typically above 100 mg/m3, correlating with higher TTCA concentrations 1.
Differential Diagnosis: Rule out other causes of parkinsonism through clinical evaluation and neuroimaging 1.Management
Primary Prevention: Minimize occupational exposure to CS2 through improved workplace ventilation and protective measures 1.
Supportive Care: Symptomatic treatment with dopaminergic agents such as levodopa, as for idiopathic Parkinson's disease, tailored to individual response 1.
Monitoring: Regular follow-up to assess progression and adjust treatment as necessary 1.Special Populations
Occupational Focus: Recommendations primarily apply to workers exposed to CS2; specific pediatric, geriatric, or pregnant population data not available 1.Key Recommendations
Monitor Urinary TTCA Levels: Regularly assess urinary TTCA concentrations as a biomarker for CS2 exposure and potential neurotoxicity (Evidence: Moderate) 1.
Implement Protective Measures: Enforce stringent workplace safety protocols to reduce CS2 exposure levels below 100 mg/m3 (Evidence: Expert opinion) 1.
Initiate Symptomatic Treatment: Begin dopaminergic therapy for parkinsonian symptoms based on clinical presentation, similar to idiopathic Parkinson's disease management (Evidence: Expert opinion) 1.References
1 van Doorn R, Delbressine LP, Leijdekkers CM, Vertin PG, Henderson PT. Identification and determination of 2-thiothiazolidine-4-carboxylic acid in urine of workers exposed to carbon disulfide. Archives of toxicology 1981. link